Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
about
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Targeting the tumor vasculature to enhance T cell activityActive immunotherapy induces antibody responses that target tumor angiogenesis.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin.Induction of antitumor immunity through xenoplacental immunization.Vaccines targeting the neovasculature of tumorsImmunization with synthetic VEGF peptides in ovarian cancerInduction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.Control of human mesothelin-expressing tumors by DNA vaccines.VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma modelUric acid enhances the antitumor immunity of dendritic cell-based vaccineCancer microenvironment and cancer vaccine.Development of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine To Protect Mice from Experimental Colitis.Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma.Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine modelCellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy.Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.Anti-angiogenesis immunotherapy.Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects.Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity.Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line.Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2.Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.The effects and mechanism of xenogeneic adipocyte vaccine for the prevention of obesity in rats.Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.
P2860
Q26778150-5CA62F7A-2569-4535-8B39-82E07612C9FBQ27026329-A7EA4A21-4BA0-4A44-97DF-DD26320FC9D5Q33772446-E32B5436-722D-4DF9-B87F-158E88CD693AQ33994533-C335ADFD-0F83-4256-859A-6CAF28F8E5B0Q34098560-81C740D2-014E-4EC8-9B32-18584BDDBB1EQ34695812-A0A079E6-64DD-497F-A787-CF8C6A8536F3Q34704905-1AD6B640-8B4A-428D-8E1B-674B050A0B9DQ34901858-550C5490-C779-4142-954E-C1929E1F316BQ35187503-8016BA72-FD61-49A4-8314-321941F93C8AQ35238497-31FCC463-858E-4656-8DCF-B8B9C59C6F1CQ35635564-A0330579-71AE-4331-8392-12A8A6CB759DQ35644324-0FDE55F8-120C-4CB1-87B4-811A1157EBC9Q36265772-AE55881B-6F93-4261-B8FB-4B3365A7870AQ36284923-FC3B70AD-D3EF-4439-BDCE-79E54EFECCFDQ36316797-E3AEEF59-9774-4222-87D6-1ACE2185CB46Q36475833-4D0BFD14-F658-4829-989D-6B28F7CEBE78Q36980421-24B7445B-9A4A-4DB7-BFAF-DBEDE8778778Q37580862-CE061EB8-840E-4950-8D8E-0ADD4E06B042Q38308139-1400D6F3-5D47-4C15-857F-DE4CA3C732D9Q39163764-C0F80032-20FD-4826-950C-94981F4C8E90Q39165919-CC557036-B480-47D7-9384-C45181776DA6Q39431474-F0944A8A-4B6F-4C27-A420-0DD2A19987AAQ39508210-7A13EC3F-EC53-46E5-BB1C-9C8EE6BD468DQ39773773-D87E7BF3-F472-4DFE-AFF4-6395F18A991BQ39888963-4522BC96-22AB-41FB-9DA4-CE4329A0A087Q40204827-A5CCE640-C0BB-49BB-A83D-44A5AA9BDFB2Q40398444-57C08448-1F18-4A0D-B3C8-79B9EAFEF8F7Q40464391-6E8DF01A-40ED-493F-9758-35641C958349Q40705863-76C30A95-87E8-4870-87FF-282AE3CEB15AQ42814797-F4078E24-D4E7-4651-8882-1E09BFBEBDA2Q45857995-94F68786-E1FE-49C7-9240-E46B17A20BADQ48511578-6BB3608E-2AA0-4B18-9FED-58BD69088B62
P2860
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@ast
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@en
type
label
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@ast
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@en
prefLabel
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@ast
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@en
P2093
P2860
P356
P1476
Immunogene therapy of tumors w ...... wth factor as a model antigen.
@en
P2093
P2860
P304
11545-11550
P356
10.1073/PNAS.191112198
P407
P577
2001-09-11T00:00:00Z